TNFRSF17 and Miyoshi myopathy: Among 24,643 MM cells analyzed by scCNV-seq, in patients who were CAR T/TCE therapy naive (n = 15 patients, 26 pre- and 9 post-CAR T/TCE samples), monoallelic or biallelic CN loss of TNFRSF17 was detected in 1.8% and 0.3% of the cells, respectively, whereas 3 and 4 or more CN gains were noted in 1.9% and 6% of the cells, respectively (Supplementary Table 5a,b and Supplementary Fig. 12a).